[{"orgOrder":0,"company":"Neuronascent","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuronascent Releases Positive Topline Phase 1a Safety Results of NNI-362 for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Neuronascent","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimers Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Neuronascent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"Neuronascent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Neuronascent
NNI-362, Neuronascent’s lead, patented, new chemical entity, was developed to reverse age-related disorders by producing new neurons to replace those lost due to chronic neurodegeneration.
NNI-351 is Neuronascent’s lead, patented, new chemical entity aimed at reversing developmental disorders by producing new neurons postnatally to enhance neurogenesis that is slowed during early development in diseases such as FXS.
NNI-362, at the two multi-doses, 120 mg and 240 mg, was shown to significantly reduce p-tau181 levels versus pre-treatment levels in study participants, also showed a significant reduction of an Alzheimer’s disease pathological biomarker.
NNI-362 is Neuronascent's lead, patented, new chemical entity developed to reverse age-related disorders by producing new neurons to replace those lost due to chronic neurodegenerative disorders.